What is claimed is:

1~~.~~ An isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to Ebola virus (EBOV) and/or an Ebola virus glycoprotein (EBOV-GP), ~~wherein the antibody has one or more of the following characteristics~~comprising:

(a) ~~comprises three~~a heavy chain complementarity determining ~~regions (CDRs) (HCDR1 , HCDR2 and HCDR3) contained within any one of the heavy chain variable~~ region ~~(HCVR) sequences selected from the group consisting of SEQ ID NOs:~~ 1 ~~8, 66, 146, 2, 34, 50, 82, 98, 1 14, 130, 162, 178, 194, 210, 226, 242, 258, 274, 290, and 306; and three light chain CDRs (LCDR1 , LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 26, 74, 154, 10, 42, 58, 90, 106, 122, 138, 170, 186, 202, 218, 234, 250, 266, 282, and 298;~~

~~(b) is a fully human monoclonal antibody;~~

~~(c) binds to EBOV, or a virus like particle (VLP) expressing an EBOV-GP with a dissociation constant (K_D) of less than 10^{-7}M , as measured in a surface plasmon resonance assay;~~

~~(d) demonstrates at least a 3 fold increase in dissociative half-life (t½) at pH 5 or pH 6 relative to pH 7.4;~~

~~(e) demonstrates neutralization of Zaire Ebola virus with an IC50 ranging from about 10^{-11} M to about 10^{-9} M;~~

~~(f) demonstrates binding to cells expressing the EBOV-GP triggering antibody-dependent cellular cytotoxicity;~~

~~(g) cross reacts with one or more strains of EBOV selected from the group consisting of Zaire.2014, Zaire.1995, Sudan, Bundibugyo and Cote d'Ivoire;~~

~~(h) binds to soluble GP (sGP);~~

~~(i) cross-competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR~~(HCDR1) amino acid

sequence ~~selected from the group consisting of any of the HCVR and LCVR~~ as set forth in SEQ ID NO: 20 with no more than one amino acid ~~sequences of Table 1 .~~

~~2. An isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to Ebola virus (EBOV) and/or~~substitution; an ~~Ebola virus glycoprotein (EBOV-GP), wherein the antibody has two or more of the following characteristics:~~

~~(a) is a fully human monoclonal antibody;~~

~~(b) binds to EBOV, or a virus like particle (VLP) expressing an EBOV-GP with a dissociation constant (K_D) of less than 10^{-7}M , as measured in a surface plasmon resonance assay;~~

~~(c) demonstrates at least a 3 fold increase in dissociative half-life (t½) at pH 5 or pH 6 relative to pH 7.4;~~

~~(d) demonstrates neutralization of Zaire Ebola virus with an IC50 ranging from about 10^{-11} M to about 10^{-9} M;~~

~~(e) demonstrates binding to cells expressing the EBOV-GP triggering antibody-dependent cellular cytotoxicity;~~

~~(f) cross reacts with one or more strains of EBOV selected from the group consisting of Zaire.2014, Zaire.1995, Sudan, Bundibugyo and Cote d'Ivoire;~~

~~(g) binds to soluble GP (sGP);~~

~~(h) cross-competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR)~~HCDR2 amino acid sequence ~~selected from the group consisting of any of the HCVR and LCVR~~as set forth in SEQ ID NO: 22 with no more than one amino acid ~~sequences of Table 1 .~~

~~3. The isolated antibody or antigen-binding fragment thereof of either claim 1 or 2, comprising a HCVR having~~substitution; an HCDR3 amino acid sequence ~~selected from the group consisting of SEQ ID NOs: 18, 66, 146, 2, 34, 50, 82, 98, 1 14, 130, 162, 178, 194, 210, 226, 242, 258, 274, 290, and 306.~~

4. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 - 3, comprising a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 74, 154, 10, 42, 58, 90, 106, 122, 138, 170, 186, 202, 218, 234, 250, 266, 282, and 298.

5. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 - 4, comprising:

(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 68, 148, 4, 36, 52, 84, 100, 1 16, 132, 164, 180, 196, 212, 228, 244, 260, 276, 292 and 308;

(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 22, 70, 150, 6, 38, 54, 86, 102, 1 18, 134, 166, 182, 198, 214, 230, 246, 262, 278, 294 and 310;

(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 24, 72, 152, 8, 40, 56, 88, 104, 120, 136, 168, 184, 200, 216, 232, 248, 264, 280, 296 and 312;

(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 28, 76, 156, 12, 44, 60, 92, 108, 124, 140, 172, 188, 204, 220, 236, 252, 268, 284 and 300;

(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 78, 158, 14, 46, 62, 94, 1 10, 126, 142, 174, 190, 206, 222, 238, 254, 270, 286 and 302;

(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 80, 160, 16, 48, 64, 96, 1 12, 128, 144, 176, 192, 208, 224, 240, 256, 272, 288 and 304.

6. The isolated antibody or antigen-binding fragment of any one of claims 1 - 5, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 18/26, 66/74, 146/154, 2/10, 34/42, 50/58, 82/90, 98/106, 1 14/122, 130/138, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298 and 306/282.

7. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 - 6, comprising an HCDR1 amino acid sequence of SEQ ID NO: 20; an HCDR2 amino acid sequence of SEQ ID NO: 22; an HCDR3 amino acid sequence of as set forth in SEQ ID NO: 24; an with no more than one amino acid substitution; a light chain complementarity determining region LCDR1 amino acid sequence ofas set forth in SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence ofas set forth in SEQ ID NO: 30 with no more than

one amino acid substitution; and an LCDR3 amino acid sequence ofas set forth in SEQ ID NO: 32. with no more than one amino acid substitution;

8. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 - 6, comprising(b) an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80. with no more than one amino acid substitution; or

9. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 - 6, comprising(c) an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 152 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 158 and with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 160.

10. An isolated monoclonal antibody or antigen-binding fragment thereof that competes for binding to EBOV and/or EBOV GP with a reference antibody or antigen-binding fragment comprising the CDRs of a HCVR, wherein the HCVR has an amino acid sequence selected from the group consisting of HCVR sequences listed in Table 1 ; and the CDRs of a LCVR, wherein the LCVR has an amino acid sequence selected from the group consisting of LCVR sequences listed in Table 1 .

1 1 . An isolated monoclonal antibody or antigen-binding fragment thereof that binds to the same epitope on EBOV and/or EBOV GP as a reference antibody or antigen-binding fragment comprising the CDRs of a HCVR, wherein the HCVR comprises an amino acid

sequence selected from the group consisting of HCVR sequences listed in Table 1 ; and the CDRs of a LCVR, wherein the LCVR comprises an amino acid sequence selected from the group consisting of LCVR sequences listed in Table 1 .

12. The isolated antibody of any one of claims 1 - 1 1 , wherein the antibody prevents attachment to and/or entry of Ebola virus into a host cell. with no more than

13. A method of neutralizing infectious EBOV, the method comprising exposing a cell infected with EBOV to a composition comprising one or more anti-EBOV antibodies or antigen-binding fragments thereof according to any one of claims 1 -12, wherein the exposing results in enhanced protection of the cell from virus infection, or from cell death.

14. The method of claim 13, wherein the infectious EBOV is neutralized in vitro or in vivo.

15. The method of claim 13, wherein the enhanced protection is observed when the antibody is used alone, or when it is used in combination with one or more additional therapeutic agents or anti-EBOV treatment modalities.

16. The method of claim 15, wherein the one or more additional therapeutic agents is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (e.g.

corticosteroids and non-steroidal anti-inflammatory drugs), a different antibody to EBOV, a vaccine for EBOV, TKM Ebola (small interfering RNAs that target viral RNA polymerase) brincidofovir (CMX-001), favipiravir (T-705), BCX-4430, AVI-7537 (antisense phosphorodiamidate morpholino oligomers that target EBOV VP24 gene) and interferons.

17. The method of claim 15, wherein the one or more additional therapeutic agents comprise one or more anti-EBOV antibodies.

18. The method of claim 17, wherein the one or more anti-EBOV antibodies comprise a heavy chain variable region (HCVR) and a light chain variable region (LCVR) amino acid sequence selected from the group consisting of any of the HCVR and LCVR amino acid sequences of Table 1 .substitution.

19.

2. The methodisolated recombinant antibody or antigen-binding fragment thereof of claim 18, wherein the one or more anti-EBOV antibodies comprise1, comprising:

(a) a heavy chain variable region (HCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 18; and a light chain variable region (LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 1 14/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298 and 306/282.having 95% sequence identity to SEQ ID NO: 26;

~~20. The method of claim 19, wherein the one or more anti-EBOV antibodies comprise a heavy chain variable region ((~~b) an HCVR~~) and a light chain variable region (LCVR)~~ amino acid sequence ~~pair selected from the group consisting of~~ having 95% sequence identity to SEQ ID ~~NOs: 18/26,~~NO: 66~~/~~; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 74; or

(c) an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 146; and ~~146/~~an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 154.

~~21.~~

3. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:

(a) an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 26;

(b) an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 74; or

(c) an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 154.

4. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:

(a) an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 26;

(b) an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 74; or

(c) an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 154.

---

5. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:

an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 3 amino acid substitutions.

6. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 3 amino acid substitutions.

7. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 3 amino acid substitutions.

8. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 2 amino acid substitutions.

9. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 2 amino acid substitutions.

10. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1, comprising:

an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 2 amino acid substitutions.

11. The isolated antibody of claim 1, wherein the antibody inhibits entry of Ebola virus into a host cell.

12. A pharmaceutical composition comprising one or more isolated monoclonal antibodies or antigen-binding fragments thereof that bind specifically to EBOV according to ~~any one of claims 1 - 12~~claim 1, and a pharmaceutically acceptable carrier or diluent.

13. ~~22.~~ The pharmaceutical composition of claim ~~21~~ 12, wherein the ~~one or more~~ isolated ~~antibodies comprise~~ monoclonal antibody or an ~~HCVR/LCVR~~antigen-binding fragment thereof comprises an HCDR1 amino acid sequence ~~pair selected from the group consisting of the HCVR and LCVR sequences listed in Table 1 .~~

~~23. The pharmaceutical composition of claim 22, wherein the HCVR/LCVR~~of SEQ ID NO: 20 with no more than one amino acid substitution; an HCDR2 amino acid sequence ~~pair is selected from the group consisting of SEQ ID NOs: 18/26, 66/74, 146/154, 2/10, 34/42, 50/58, 82/90, 98/106, 114/122, 130/138, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298 and 306/282.~~

~~24. The pharmaceutical composition of claim 23, wherein the HCVR/LCVR~~of SEQ ID NO: 22 with no more than one amino acid substitution; an HCDR3 amino acid sequence ~~pair is selected from the group consisting~~of SEQ ID NO: 24 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID ~~NOs: 18/26, 66/74 and 146/154.~~

~~25. A pharmaceutical composition comprising (a) a first anti-EBOV antibody or an antigen-binding fragment thereof; (b) a second anti-EBOV antibody or antigen-binding fragment thereof; and (c) a third anti-EBOV antibody or antigen-binding fragment thereof, according to any one of claims 1 -12, wherein the first antibody binds to, or interacts with, a first epitope on EBOV and the second and/or third antibody binds to, or interact(s) with a different epitope on EBOV, and (d)~~ NO: 30 with no more

than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 32 with no more than one amino acid substitution, and a pharmaceutically acceptable carrier or diluent.

~~26.~~

14. The pharmaceutical composition of claim ~~25, wherein the first, second and third anti-EBOV antibodies comprise an HCVR/LCVR amino acid sequence pair selected from the group consisting of the HCVR and LCVR sequences listed in Table 1 .~~

~~27. The pharmaceutical composition of claim 25, wherein the epitopes that bind to, or interact with, the first, second and/or third anti-EBOV antibodies or antigen-binding fragments thereof, are distinct and non-overlapping.~~

~~28. The pharmaceutical composition of claim 25, wherein the first anti-EBOV antibody or an antigen-binding fragment thereof binds to, or interacts with one epitope on one strain of EBOV and the second and/or third anti-EBOV antibody or an antigen-binding fragment~~

~~thereof binds to, or interacts with a second and/or a third epitope on the same strain or on a different strain of EBOV.~~

~~29. The pharmaceutical composition of claim 28, wherein the EBOV strains are selected from the group consisting of the Zaire.2014, Zaire.1995, Sudan, Bundibugyo, and Cote d'Ivoire strains.~~

~~30. A pharmaceutical composition comprising a first~~ 12, wherein the isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution.

15. ~~that binds specifically to EBOV~~ The pharmaceutical composition of claim 12, wherein the ~~first~~ isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: ~~20~~148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: ~~22~~150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: ~~24~~152 with no more than one

amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 28156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 30158 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 32, and a pharmaceutically acceptable carrier or diluent.160 with no more than one amino acid substitution.

31 . The pharmaceutical composition of claim 30, further comprising a second isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to EBOV, wherein the second isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 68; an HCDR2 amino acid sequence of SEQ ID NO: 70; an HCDR3 amino acid sequence of SEQ ID NO: 72; an LCDR1 amino acid sequence of SEQ ID NO: 76; an LCDR2 amino acid sequence of SEQ ID NO: 78 and an LCDR3 amino acid sequence of SEQ ID NO: 80.

32. The pharmaceutical composition of claim 31 , further comprising a third isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to EBOV, wherein the third isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 148; an HCDR2 amino acid sequence of SEQ ID NO: 150; an HCDR3 amino acid sequence of SEQ ID NO: 152; an LCDR1 amino acid sequence of SEQ ID NO: 156; an LCDR2 amino acid sequence of SEQ ID NO: 158 and an LCDR3 amino acid sequence of SEQ ID NO: 160.

33.

16. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes an HCVR, and/or an LCVR of an antibody as set forth in any one of claims 1 - 12.claim 1.

17. 34. A vector comprising the polynucleotide sequence of claim 33.16.

35. A

18. An isolated cell expressing the vector of claim 3417.

36. A method of preventing, treating or ameliorating at least one symptom of EBOV infection, or of decreasing the frequency or severity of at least one symptom of EBOV infection, the method comprising administering an antibody or antigen-binding fragment of any one of claims 1 - 12 or a pharmaceutical composition of claims 21 - 31 to a subject in need thereof.

37. The method of claim 36, comprising administering an antibody cocktail comprising a mixture of at least two anti-EBOV antibodies.

38. The method of either claim 36 or 37, comprising administering an antibody cocktail comprising a mixture of three anti-EBOV antibodies, wherein the three anti-EBOV antibodies comprise HCVR/LCVR amino acid sequence pairs as set forth in SEQ ID NOs: 18/26, 66/74 and 146/154.

39. The method of claim 36, wherein the at least one symptom is selected from the group consisting of fever, headache, fatigue, loss of appetite, myalgia, diarrhea, vomiting, abdominal pain, dehydration and unexplained bleeding.

40. The method of claim 36, wherein the pharmaceutical composition is administered prophylactically or therapeutically to the subject in need thereof.

41 . The method of claim 40, wherein the subject in need thereof is a subject suffering from an infection with EBOV, or a subject exposed to, or at risk for exposure to EBOV, or of acquiring an EBOV infection, wherein the subject is selected from the group consisting of an immunocompromised individual, a healthcare worker, a person who is suspected of having been exposed to a person harboring the Ebola virus, a person who comes into physical contact or close physical proximity with an infected individual, a hospital employee, a pharmaceutical researcher, maintenance personnel responsible for cleaning a hospital facility or institution where an Ebola patient has been treated, individuals who have visited or are planning to visit an area or country known to have or suspected to have an outbreak of Ebola virus and a frequent flyer.

42. The method of any one of claims 36 - 41 , wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof is administered in combination with a second therapeutic agent.

43. The method of claim 42, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (e.g. corticosteroids and non-steroidal anti-inflammatory drugs), a different antibody to EBOV, a vaccine for EBOV, TKM Ebola (small interfering RNAs that target viral RNA polymerase) brincidofovir (CMX-001), favipiravir (T-705), BCX-4430, AVI-7537 (antisense phosphorodiamidate morpholino oligomers that target Ebola virus VP24 gene) and interferons.

44. The method of any one of claims 36 - 43, wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermal^, intramuscularly, intranasally, or orally.

45. A method of increasing survival, or the likelihood of survival of a subject suffering from infection with EBOV, or a subject exposed to EBOV, or at risk for exposure to, or for acquiring EBOV, the

method comprising administering at least one antibody or antigen-binding fragment of any one of claims 1 - 12, or a pharmaceutical composition of any of claims 21 - 31 to a subject in need thereof.

46. The method of claim 45, comprising administering an antibody cocktail comprising a mixture of at least two anti-EBOV antibodies.

47. The method of either claim 45 or 46, comprising administering an antibody cocktail comprising a mixture of three anti-EBOV antibodies, wherein the three anti-EBOV antibodies comprise HCVR/LCVR amino acid sequence pairs as set forth in SEQ ID NOs: 18/26, 66/74 and 146/154.

48. The method of any one of claims 45 - 47, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or the antibody cocktail is administered prophylactically or

therapeutically to the subject in need thereof.

49. The method of any one of claims 45 - 48, wherein the subject in need thereof who is at risk for exposure to, or for acquiring an EBOV infection is selected from the group consisting of an immunocompromised individual, a healthcare worker, a person who is suspected of having been exposed to a person harboring the Ebola virus, a person who comes into physical contact or close physical proximity with an infected individual, a hospital employee, a pharmaceutical researcher, maintenance personnel responsible for cleaning a hospital facility or institution where an Ebola patient has been treated, individuals who have visited or are planning to visit an area or country known to have or suspected to have an outbreak of Ebola virus and a frequent flyer.

50. The method of any one of claims 45 - 49, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen binding fragment thereof, or the antibody cocktail is administered in combination with a second therapeutic agent.

51 . The method of claim 50, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug (e.g. corticosteroids and non-steroidal anti-inflammatory drugs), a different antibody to EBOV, a vaccine for EBOV, TKM Ebola (small interfering RNAs that target viral RNA polymerase) brincidofovir (CMX-001), favipiravir (T-705), BCX-4430, AVI-7537 (antisense phosphorodiamidate morpholino oligomers that target Ebola virus VP24 gene) and interferons.

52. The method of any one of claims 45 - 51 , wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.